Introduction {#S0001}
============

The increased risk of premature death in morbidly obese individuals is strongly associated with type 2 diabetes mellitus (T2DM) and its complications. Insulin resistance (IR) has been recognized as the essential step in development of T2DM \[[@CIT0001]--[@CIT0004]\]. The accelerated insulin production and secretion required to balance the plasma glucose level lead progressively to β-cell dysfunction and further development of the disease. Decreased calorie consumption, increased caloric metabolism and the resulting weight loss can theoretically invert this unfavorable trend and improve the course of T2DM \[[@CIT0005]--[@CIT0008]\]. This recommended first line treatment, however, seems to be insufficient on its own in long-term observations and leads to additional bariatric procedures to help prevent the global and individual hazards of diabetes progression \[[@CIT0009]--[@CIT0011]\]. The emerging data underline that bariatric surgery may provide a more sustained and effective treatment for obesity and its related diseases including T2DM \[[@CIT0012]--[@CIT0015]\].

The surgical methods currently accepted in the bariatric world -- sleeve gastrectomy (SG), gastric bypass (GB) with its variations, and biliopancreatic diversion/duodenal switch (BPD/DS) -- present different modifications of metabolic mechanisms, but all reduce calorie intake as their primary function, leading to body fat reduction \[[@CIT0016]--[@CIT0020]\].

The previously mentioned fat deposits are the critical factor in impaired insulin function; thus weight reduction must result in improved glucose metabolism \[[@CIT0021], [@CIT0022]\].

Many recent studies have shown that the modification of gastro-intestinal hormone activity following bariatric surgery, particularly related to the effects of incretin, may support or even initiate better metabolic management, especially following intestinal bypassing procedures \[[@CIT0023]--[@CIT0026]\].

The observation of the change in the hormonal profile influencing IR a few days after GB procedures showed that the key mechanism in improving IR was addressed \[[@CIT0026]\]. This vital shift was evidenced by not only the lack of significant body mass reduction, but also the lack of initiation of incretin-related mechanisms dependent on oral food intake \[[@CIT0026]\].

A number of meta-analyses have reported that glucose metabolism was significantly corrected at 2 weeks following GB and BPD/DS procedures. Faria *et al*. based on HOMA-IR assessment observed more rapid improvement of IR as early as 3 days following Roux-en-Y gastric bypass (RYGB) \[[@CIT0027]\].

This phenomenon corresponds with clinical reports of some diabetic patients being discharged without anti-diabetic medications just a few days after their GB surgery \[[@CIT0028]--[@CIT0031]\].

Despite many reports dedicated to this issue, there is still no comprehensive hypothesis explaining the rapid response following GB procedures.

One theory, proposed by Pournanras *et al*. \[[@CIT0032]\], concerns the signaling role of bile and its components, represented by bile acids (BA) reabsorbed by the portal circulation, in rapid glucose control. Elevated concentrations of BA in the blood are believed to be strongly linked to the improvement of glycemic metabolism, therefore suggesting that surgical procedures in which undiluted bile is transported via a long section of the small intestine excluded from food passage may be a significant factor.

The supreme effectiveness in T2DM resolution after BPD/DS \[[@CIT0016]\], in which the biliary limb (BL) is designed to be much longer than the alimentary limb (AL), in contrast to that in RYGB, may be partially explained by the above-mentioned mechanism \[[@CIT0033]--[@CIT0035]\]. Moreover, one-anastomosis gastric bypass (OAGB), the bariatric procedure designed to be a more feasible modification of the gastric bypass, demonstrates greater similarity to BPD/DS than to RYGB in long-term assessment \[[@CIT0036]\]. The significantly longer undiluted bile transit in the bypassed portion of the gastrointestinal (GI) tract in OAGB and BPD/DS as opposed to RYGB may be considered as the deciding factor in the endocrine anti-diabetic mechanism. What should be emphasized here is that the length of the small intestine distally to the site of initial mixing of food with biliopancreatic juice is almost equal in both forms of the GB. Therefore the intestinal capacity responsible for the calorie intake remains comparable.

Despite many controversies concerning the long-term functional results of OAGB, its metabolic profile has been widely accepted, and this GB modification is currently regarded by many as a distinct procedure \[[@CIT0036]--[@CIT0039]\].

The primary objective of this prospective randomized study was to assess the changes in the main laboratory parameters of glucose metabolism and determine the IR evolution from the time of the initial preoperative visit until the 6-month follow-up consultation, exposing the significance of the ultra-fast postoperative response while comparing the 3 bariatric methods, with the belief that the degree of metabolic effect may be correlated with different anatomical combinations.

The authors attempted to investigate whether the extreme calorie restriction in the first 4 postoperative days may be considered as the sole key factor of IR improvement or if the hormonal advantages resulting from duodeno-intestinal exclusion should be recognized as the most significant mechanism in glycemic control. Sleeve gastrectomy as a pure restrictive procedure and two types of gastric bypass were selected for the comparison to try to resolve this question. The results after RYGB vs. OAGB, where the main difference was the length of the BL, verify the theory of the role of the bile components in the hormonal mechanism of glucose metabolism control.

Material and methods {#S0002}
====================

From January to December 2013, a cohort of 90 severely obese individuals with a body mass index (BMI) in the range 35--55 were recruited to the prospective study. The main inclusion criterion, apart from morbid obesity, was the impairment of glucose tolerance, defined as a homeostatic model assessment-insulin resistance (HOMA-IR) formula value \> 2.5 \[[@CIT0040]\]. Patients receiving anti-diabetic or other hormonal medications were not included in the investigation. Patients suffering from diseases seriously affecting glucose homeostasis were also initially excluded.

Morbid obesity was the basic indication for the operation. All of the patients met the IFSO criteria \[[@CIT0041]\].

The patients enrolled in the study were consecutively divided into 3 equal groups of 30: sleeve gastrectomy (SG), Roux-en-Y gastric bypass (RYGB), and one-anastomosis gastric bypass (OAGB).

Regardless of the procedure allocation, all of the patients completed the preoperative 3-month preparation period, which consisted of a low-calorie diet (1000--1200 kcal/day) and psychological management. In order to reduce the risk of perioperative complications and adverse events, patients were trained on how to reduce food intake and how to control their eating drive and to adapt to the postoperative change of the GI tract anatomy.

The operations were performed laparoscopically following the techniques described in published materials \[[@CIT0042], [@CIT0043]\].

A 36 Fr calibration tube was used to confirm volume restriction of the gastric sleeve or pouch (volume ca 40 ml). Because a long and narrow gastric pouch was constructed in OAGB to reduce the risk of bile reflux, the same type of gastric tube was used in RYGB procedures to create similar restriction conditions for the comparison.

The continuity of the digestive tract in SG was preserved, and no exclusion of the intestine was performed. The length of the intestinal loops excluded from mixed food and biliopancreatic content in GB operations was equal and measured intraoperatively 250 cm but in different combinations according to the type of the procedure. The extent of the common limb was therefore left equal. The scheme of the procedures is shown in [Figure 1](#F0001){ref-type="fig"}.

![Scheme of the procedures](WIITM-10-25212-g001){#F0001}

All but 3 complicated patients were discharged home on the 4^th^ postoperative day after laboratory tests. They were provided with a detailed dietary plan to prevent alimentary deficiencies.

The total observation period consisted of 5 phases starting with the initial visit then progressing in the perioperative period lasting 9 months, and was scheduled as shown in [Table I](#T0001){ref-type="table"}.

###### 

Observation periods and time points

  Phase   Period/time points   Duration   Specification
  ------- -------------------- ---------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  1       ini--0D              3 months   From initial preoperative visit until the day of admission to the hospital. The phase when the influence of the preparative low calorie diet (ca 1000--1200 kcal/ day) may be observed
  2       0D--4D               5 days     From the day of admission until the day of discharge from the hospital. The phase when patients did not initiate eating (only clear fluids orally), therefore the effect of the operation and extreme calorie restriction can be observed
  3       4D--1M               1 month    From the day of discharge until the end of 1^st^ postoperative month. The phase when only the low calorie/low volume diet may have influence on the IR result
  4       1M--3M               2 months   From the of end of the 1^st^ postoperative month until the end of 3^rd^ postoperative month. The phase when additional moderate weight/fat reduction may contribute to IR improvement
  5       3M--6M               3 months   From the end of 3^rd^ to 6^th^ postoperative month. The phase when remarkable weight/fat reduction may additionally influence IR

Blood samples were collected after an overnight fast during the initial visit (ini) and during the following checkpoints: day 0 (0D), day 4 (4D), and 1, 3 and 6 months (1M, 3M, 6M) after the surgery. According to the protocol, such parameters as glucose and insulin levels were measured (INI, 0D, 4D, 1M, 3M, 6M), whereas IR was calculated using the HOMA-IR formula (glucose × insulin /405) \[[@CIT0044]\]. Glycosylated hemoglobin (HbA~1c~%) was determined at the time points ini, 3M, and 6M. Finally, BMI measurement was performed initially, after the preoperative 3-month preparation period, then 1 month, 3 months, and 6 months after the operation.

Although the blood tests included the blood lipid values, the authors decided not to attach results in the description to avoid blurring the main concept of the study.

All analyses were performed in the Central Hospital Laboratory using the Abbot Architect CI8200 automated clinical chemistry analyzer. HbA~1c~ levels were determined by ion-exchange high-performance liquid chromatography (HPLC).

The scope, methodology and assumptions of the study were accepted by the local bioethical committee of the Medical University of Gdansk, Poland.

Statistical analysis {#S20003}
--------------------

Statistical calculation was performed with the SPSS package, using one-way ANOVA with post-hoc Bonferroni.

Longitudinal analysis was calculated comparing the present results to previous and basic checkpoints. Statistical significance was set at *p* \< 0.05.

Results {#S0004}
=======

From the total group of 90 cases, 9 patients (6 from SG and 3 from RYGB) were excluded due to issues that could interfere with the results. The list of patients and the reason for exclusion are presented in [Figure 2](#F0002){ref-type="fig"}.

![Patients excluded from the study](WIITM-10-25212-g002){#F0002}

Power calculation was performed a priori. With a significance level of 0.05, three groups, a power of at least 85% and expectation of a large effect (*f* = 0.40), the total required sample size was calculated for a minimum of 72 objects. Leven\'s test revealed homogeneity within the groups (*p* \> 0.05).

The initial mean parameters of glucose metabolism as well as the main demographic variables were comparable in the 3 groups and are detailed in [Table II](#T0002){ref-type="table"}.

###### 

Characteristics of the included patients on the initial visit

  Preoperative parameters (INI)   SG (*n* = 24)       RYGB (*n* = 27)       OAGB (*n* = 30)                          
  ------------------------------- ------------------- --------------------- --------------------- --------- -------- ------
  Age                             43.3                12.4                  44.3                  12.1      45       9.8
  Male/female                     6/18                                      7/20                            10/20    
  BMI \[kg/m^2^\]                 45.90               6.52                  43.99                 5.89      45.92    4.82
  Weight \[kg\]                   132.3               12.7                  128.9                 16.5      131.4    17.1
  Obesity evolution \[years\]     19.2                11.2                  21.8                  12.1      22.5     10.2
  Glucose \[mg/dl\]               108.54              14.60                 106.22                14.97     110.27   12.6
  Insulin \[µUI/l\]               17.17               4.31                  17.83                 5.66      17.79    4.52
  HOMA-IR                         4.60                1.53                  4.79                  2.02      4.93     1.65
  HbA~1c~                         6.06                0.34                  6.08                  0.59      6.06     0.27
  **Parameter**                   **SG (*n* = 24)**   **RYGB (*n* = 27)**   **OAGB (*n* = 30)**                      
  ***n***                         **%**               ***n***               **%**                 ***n***   **%**    
  Dyslipidemia                    23                  95.8                  25                    92.6      26       86.6
  Hypertension                    21                  87.5                  24                    88.9      25       83.3
  Arthropathy                     8                   33.3                  8                     29.6      11       36.6
  GERD                            5                   20.8                  7                     25.9      7        23.3
  Sleep apnea                     3                   12.5                  4                     14.8      4        13.3
  Asthma                          2                   8.3                   3                     11.1      3        10
  Psoriasis                       1                   4.2                   2                     7.4       1        3.3

There were no postoperative deaths in the investigated groups. Apart from 2 excluded patients from the RYGB and SG groups who experienced a pulmonary embolism and 1 RYGB patient who experienced postoperative bleeding requiring reoperation 12 h after the surgery, no major complications were observed. Gastritis was diagnosed in 2 patients after SG (8.3%) and ulceration in the pouch-jejunum anastomosis was diagnosed in 3 patients after RYGB (11.1%) 6 months after the procedures. Only 2 patients complained of persistent biliary reflux episodes up to 1 month after OAGB, but the symptoms passed without any treatment. Episodes of hypoglycemia (glucose \< 70 mg%) were experienced postoperatively by almost half of the patients (SG 50%, RYGB 40.7%, OAGB 53.3%) but were treated by means of dietary correction. Only 10 patients reported hypoglycemic episodes later than 30 days after the procedure. There was no need to control glucose levels with anti-diabetic medications up to the 6-month postoperative checkpoint in all but 1 patient, who had to be excluded due to single doses of insulin administration in the first 2 days after SG. The adverse postoperative events are listed in [Table III](#T0003){ref-type="table"}.

###### 

Postoperative adverse events

                                                SG (*n* = 24)   RYGB (*n* = 27)   OAGB (*n* = 30)               
  --------------------------------------------- --------------- ----------------- ----------------- ------ ---- ------
  **Adverse events \< 30 days**                                                                                 
  Hypoglycemia episodes                         13              54.2              13                48.2   17   56.6
  Constipation episodes                         9               37.5              10                37     5    16.7
  Vomiting episodes                             6               25                7                 25.9   7    23.3
  Diarrhea                                      1               4.2               6                 22.2   9    30
  Persistent biliary reflux                     0                                 0                        2    6.7
  **Adverse events \> 30 days**                                                                                 
  GERD                                          4               16.7              0                        0    
  Hypoglycemia episodes                         5               20.8              4                 14.8   5    16.7
  Gastritis or pouchitis                        2               8.3               1                 3.7    1    3.3
  Hypoalbuminemia                               3               12.5              5                 18.5   7    23.3
  Anemia                                        2               8.3               3                 11.1   5    16.7
  Iron deficiency                               2               8.3               3                 11.1   5    16.7
  Vit B~12~ deficiency                          0                                 0                        1    3.3
  Vit D~3~ deficiency                           6               24                6                 22.2   9    30
  Diarrhea                                      0                                 3                 11.1   5    16.7
  Ulceration of the pouch-jejunal anastomosis   --                                3                 11.1   0    

In the total 9-month period of observation (including the 3-month preoperative preparation), relevant improvement of the main parameters of glucose metabolism was observed in all 3 groups.

Reduced calorie intake to 1000--1200 kcal in the preoperative period in patients awaiting surgery (phase 1), which led to weight reduction (3.3--4.5 BMI points), resulted in approximately a 20% improvement (SG 16.73%, RYGB 20.46%, OAGB 21.3%) of the HOMA-IR index.

However, the most spectacular insulin sensitivity change was observed in the first 4 days after surgery (Phase 2). The decrease of HOMA-IR at 4 days after surgery compared to the preoperative value (D0) was significantly higher in gastric bypass groups than in patients after pure restrictive surgery: OAGB --2.44 (--63%), RYGB --2.14 (--56%), vs. SG --1.57 (--41%). The difference between the BP groups was noticeable, favoring OAGB over RYGB. The change of HOMA-IR postoperatively is shown in [Figure 3](#F0003){ref-type="fig"}.

![HOMA-IR improvement 4 days after surgery (compared to 0D)](WIITM-10-25212-g003){#F0003}

Though the trend of insulin resistance improvement was observed in all phases, the HOMA-IR levels on the 4^th^ postoperative day were not significantly different from values at 1, 3, and 6 months in all groups. They are detailed in [Table IV](#T0004){ref-type="table"} and [Figures 4](#F0004){ref-type="fig"}, [5](#F0005){ref-type="fig"}.

![Evolution of HOMA-IR](WIITM-10-25212-g004){#F0004}

![HOMA-IR improvement compared to initial value](WIITM-10-25212-g005){#F0005}

###### 

Change of HOMA-IR

  Checkpoint            Mean   SD     Δ (initial)   Value of *p*   Δ (previous)   Value of *p*
  --------------------- ------ ------ ------------- -------------- -------------- --------------
  **SG (*n* = 24)**                                                               
  INI                   4.60   1.53                                               
  0D                    3.83   1.36   −0.77         0.0065         −0.77          0.0065
  4D                    2.26   0.81   −2.34         \< 0.0001      −1.57          \< 0.0001
  1M                    2.04   0.80   −2.56         \< 0.0001      −0.22          0.3591
  3M                    1.87   0.61   −2.73         \< 0.0001      −0.17          0.4221
  6M                    1.59   0.56   −3.01         \< 0.0001      −0.28          0.1120
  **RYGB (*n* = 27)**                                                             
  INI                   4.79   2.02                                               
  0D                    3.81   2.05   −0.98         0.0827         −0.98          0.0827
  4D                    1.67   0.61   −3.12         \< 0.0001      −2.14          \< 0.0001
  1M                    1.55   0.54   −3.24         \< 0.0001      −0.12          0.4475
  3M                    1.33   0.46   −3.46         \< 0.0001      −0.22          0.1131
  6M                    1.21   0.44   −3.58         \< 0.0001      −0.12          0.3318
  **OAGB (*n* = 30)**                                                             
  INI                   4.93   1.65                                               
  0D                    3.88   1.51   −1.05         0.0127         −1.05          0.0127
  4D                    1.44   0.55   −3.49         \< 0.0001      −2.44          \< 0.0001
  1M                    1.37   0.51   −3.56         \< 0.0001      −0.07          0.6112
  3M                    1.29   0.47   −3.64         \< 0.0001      −0.07          0.5300
  6M                    1.11   0.33   −3.82         \< 0.0001      −0.19          0.0914

While the drop of insulin level was the key variable influencing the postoperative ultra-fast HOMA-IR decrease, the low plasma glucose was the deciding factor in the longer term of the postoperative period in phases 3--5, especially in OAGB patients ([Figures 6](#F0006){ref-type="fig"}--[8](#F0008){ref-type="fig"}).

![Evolution of insulin level](WIITM-10-25212-g006){#F0006}

![Evolution of glucose level](WIITM-10-25212-g007){#F0007}

![Evolution of HbA~1c~](WIITM-10-25212-g008){#F0008}

In the total 9-month period of observation, differences in BMI values (ΔBMI, %ΔBMI) of --10.2 (--22.2%) after SG, --14.1 (--32.1%) after RYGB, and --16.5 (--36.4%) after OAGB were observed. The evolution of BMI is shown in [Figure 9](#F0009){ref-type="fig"}.

![Evolution of BMI](WIITM-10-25212-g009){#F0009}

The HOMA-IR improvement accompanied the weight and body fat reduction in the 3-month preparation period but was not so strongly dependent on BMI decrease in the 1--6 months following surgery.

The early outcomes suggest that the mechanisms of IR control functioning in phase 2 (0D--4D) are the most crucial during the entire observation period. The results demonstrated that the procedures based on duodeno-intestinal exclusion involve a mechanism which more intensively influences IR improvement than only pure restriction does. Moreover, the length of the biliary limb and therefore the concentrated bile transit may play an important role in the glucose metabolism change. Detailed data are presented in [Tables IV](#T0004){ref-type="table"}--[VIII](#T0008){ref-type="table"}.

###### 

Change of mean plasma insulin level

  Checkpoint            Mean    SD     Δ (initial)   Value of *p*   Δ (previous)   Value of *p*
  --------------------- ------- ------ ------------- -------------- -------------- --------------
  **SG (*n* = 24)**                                                                
  INI                   17.17   4.31                                               
  0D                    14.75   4.12   −2.42         0.0580         −2.42          0.0580
  4D                    9.20    2.71   −7.97         \< 0.0001      −5.55          \< 0.0001
  1M                    8.48    2.64   −8.70         \< 0.0001      −0.73          0.3664
  3M                    8.18    2.50   −8.99         \< 0.0001      −0.30          0.6942
  6M                    7.15    1.74   −10.02        \< 0.0001      −1.03          0.1120
  **RYGB (*n* = 27)**                                                              
  INI                   17.83   5.66                                               
  0D                    14.18   5.38   −3.65         0.0186         −3.65          0.0186
  4D                    7.27    2.54   −10.57        \< 0.0001      −6.91          \< 0.0001
  1M                    6.95    2.44   −10.88        \< 0.0001      −0.31          0.6181
  3M                    5.89    1.60   −11.94        \< 0.0001      −1.06          0.0647
  6M                    5.51    1.90   −12.32        \< 0.0001      −0.37          0.4303
  **OAGB (*n* = 30)**                                                              
  INI                   17.79   4.52                                               
  0D                    14.98   4.6    −2.81         0.0203         −2.81          0.0203
  4D                    6.42    1.97   −11.37        \< 0.0001      −8.56          \< 0.0001
  1M                    6.22    2.31   −11.57        \< 0.0001      −0.2           0.7195
  3M                    6.15    2.07   −11.64        \< 0.0001      −0.07          0.9021
  6M                    5.51    1.6    −12.28        \< 0.0001      −0.64          0.1855

###### 

Change of mean plasma glucose level

  Checkpoint            Mean     SD      Δ (initial)   Value of *p*   Δ (previous)   Value of *p*
  --------------------- -------- ------- ------------- -------------- -------------- --------------
  **SG (*n* = 24)**                                                                  
  INI                   108.54   14.60                                               
  0D                    103.54   14.57   −5.00         0.2513         −5.00          0.2513
  4D                    99.04    14.16   −9.50         0.0302         −4.50          0.2939
  1M                    96.71    12.20   −11.83        0.0047         −2.33          0.5530
  3M                    92.79    11.22   −15.75        0.0002         −3.92          0.2628
  6M                    90.21    11.02   −18.33        \< 0.0001      −2.58          0.4356
  **RYGB (*n* = 27)**                                                                
  INI                   106.22   14.97                                               
  0D                    104.93   18.37   −1.29         0.7784         −1.29          0.7784
  4D                    92.81    11.33   −13.41        0.0005         −12.12         0.0052
  1M                    90.82    8.98    −15.4         \< 0.0001      −1.99          0.4777
  3M                    90.52    10.74   −15.7         \< 0.0001      −0.3           0.9118
  6M                    88.37    8.3     −17.85        \< 0.0001      −2.15          0.4142
  **OAGB (*n* = 30)**                                                                
  INI                   110.27   12.6                                                
  0D                    102.5    13.33   −7.77         0.0239         −7.77          0.0239
  4D                    89.73    10.5    −20.54        \< 0.0001      −12.77         0.0001
  1M                    89.07    8.16    −21.2         \< 0.0001      −0.66          0.7867
  3M                    84.8     6.47    −25.47        \< 0.0001      −4.27          0.0285
  6M                    81.4     4.46    −28.87        \< 0.0001      −3.4           0.0211

###### 

Change of mean HbA~1c~

  Checkpoint            Mean   SD     Δ (initial)   Value of *p*   Δ (previous)   Value of *p*
  --------------------- ------ ------ ------------- -------------- -------------- --------------
  **SG (*n* = 24)**                                                               
  INI                   6.06   0.34                                               
  3M                    5.72   0.39   −0.34         0.0029         −0.35          0.0029
  6M                    5.61   0.34   −0.45         \< 0.0001      −0.11          0.3135
  **RYGB (*n* = 27)**                                                             
  INI                   6.08   0.59                                               
  3M                    5.63   0.31   −0.45         0.0009         −0.45          0.0009
  6M                    5.4    0.29   −0.68         \< 0.0001      −0.23          0.0069
  **OAGB (*n* = 30)**                                                             
  INI                   6.06   0.27                                               
  3M                    5.47   0.32   −0.59         \< 0.0001      −0.59          \< 0.0001
  6M                    5.3    0.33   −0.76         \< 0.0001      −0.17          0.0474

###### 

Change of BMI

  Checkpoint            Mean    SD     Δ (initial)   Value of *p*   Δ (previous)   Value of *p*
  --------------------- ------- ------ ------------- -------------- -------------- --------------
  **SG (*n* = 24)**                                                                
  INI                   45.90   6.52                                               
  0D                    42.13   6.27   −3.77         0.0518         −3.77          0.0518
  1M                    41.90   6.00   −4.00         0.0359         −0.23          0.8994
  3M                    38.00   6.54   −7.90         0.0002         −3.90          0.0408
  6M                    35.70   6.55   −10.20        \< 0.0001      −2.30          0.2398
  **RYGB (*n* = 27)**                                                              
  INI                   43.99   5.89                                               
  0D                    40.66   6      −3.33         0.0446         −3.33          0.0446
  1M                    39.04   5.12   −4.95         0.0018         −1.62          0.2908
  3M                    34.08   5.83   −9.91         \< 0.0001      −4.96          0.0016
  6M                    29.85   5.14   −14.14        \< 0.0001      −4.23          0.0066
  **OAGB (*n* = 30)**                                                              
  INI                   45.32   4.82                                               
  0D                    40.77   4.18   −4.55         0.0002         −4.55          0.0002
  1M                    39.69   4.32   −5.63         \< 0.0001      −1.08          0.3292
  3M                    32.8    3.94   −12.52        \< 0.0001      −6.89          \< 0.0001
  6M                    28.8    3.26   −16.52        \< 0.0001      −4.00          \< 0.0001

Discussion {#S0005}
==========

Because the medical and demographic prognoses for the next 25 years present an alarming threat of a worldwide diabetes epidemic \[[@CIT0045]\], the call for more intensive research to develop effective therapeutic models to prevent, treat, or at least slow down this detrimental trend should be propagated. Although bariatric surgery has recently been recognized as the most effective method of T2DM management, as supported by multiple scientific studies, many believe that understanding the mechanism of glucose metabolism based on the investigations of operated patients may lead to the invention of novel non-invasive therapies \[[@CIT0046], [@CIT0047]\].

Recently, despite the unclear mechanism of action, gastric bypass and biliopancreatic diversion/duodenal switch have been used for T2DM treatment, as they are recognized as the most effective surgical procedures. It is commonly observed that the rapid postoperative improvement of glycemic control is weight loss independent. The remission or partial remission of T2DM is experienced within the first postoperative month when the weight reduction is not significant \[[@CIT0024], [@CIT0025], [@CIT0048]\]. It has been well documented that enhanced insulin secretion and decreased insulin resistance are associated with higher activity of the well-known human incretin, glucagon-like peptide-1 (GLP-1), in the early response after bypass procedures \[[@CIT0024], [@CIT0025]\].

A positive byproduct of the studies involving RYGB and BPD-DS patients was the discovery and production of medications that enhance incretin activity \[[@CIT0049]\].

Though the effectiveness of incretin analogues in T2DM therapy has already been proven, the alteration of glucose metabolism via an enhanced incretin effect appears to be only a supporting and not primary mechanism in diabetics who experienced immediate or early remission after gastric bypass surgery. It has been reported that blocking this mechanism using different anti-incretin agents in patients after RYGB is less influential than previously believed and cannot definitely hamper IR improvement \[[@CIT0050]\].

Furthermore, over 50% of diabetic patients experience an immediate improvement of glucose balance without anti-diabetic medications within just a few postoperative days when they are discharged home before initiating per os feeding (only clear fluids), which is the condition generally considered to be indispensable to provoke the incretin reactions \[[@CIT0027], [@CIT0051], [@CIT0052]\]. Such impressive clinical observations were noted to occur more often after BP operations as opposed to solely restrictive procedures \[[@CIT0053]\].

Some authors question such a rapid response following gastric bypass or claim that prolonged calorie restriction is the source of the quick improvement in IR, a status which accompanies all extensive GI surgery \[[@CIT0054]\].

Additionally, studies based on hyperinsulinemic euglycemic clamp have confirmed the fast IR improvement, but still the interval from the surgery to assessment was not shorter than a few weeks, which does not definitively correlate with the clinical observations \[[@CIT0055], [@CIT0056]\].

In order to support some extra metabolic value of GB procedures compared to the pure restrictive operations, the authors of this study prospectively assessed the main laboratory parameters of glucose metabolism in obese individuals with IR in different stages of the bariatric management, comparing patients who underwent sleeve gastrectomy and two types of gastric bypass.

To ensure a similar restrictive component, the gastric reservoirs in both SG and GB were constructed in the same manner.

Like other researchers \[[@CIT0027]\], we chose a very simple parameter, HOMA-IR, to measure insulin sensitivity, deciding against a more precise one dedicated for IR assessment tests such as clamp. This solution, convenient for the investigated subjects because of its non-invasiveness, was well tolerated and enabled us to recruit a representative number of patients to each group (3 × 30) in quite a short time.

As expected, IR improvement was observed (ca 20%) in the preoperative 3-month preparation period when patients in all groups reduced their daily energy intake to ca 1000-1200 kcal. It was not so spectacular compared to what was observed in the first 4 days postoperatively, when HOMA-IR decreased 41--63% from the value obtained on the day of admission for surgery. The significant difference of ΔHOMA-IR between the pure restrictive procedure (SG) and RYGB or OAGB exposed, apart from the result of extreme caloric restriction, the additional important role of the excluded part of the digestive tract in alteration of glucose homeostasis.

We observed the same trend during the follow-up visits (1--6 months), as previously reported by Faria *et al*. \[[@CIT0027]\], that the HOMA-IR evolved smoothly down in consecutive periods postoperatively, but the change was never so remarkable as directly after the surgery, even in the stages when incretin mechanisms could be strongly initiated or weight/fat reduction could influence the IR improvement.

The ultra-fast response after GB procedures may support Rubino\'s "foregut theory" \[[@CIT0057]\] propagating the key role of glucose metabolism improvement resulting from the exclusion of the duodenum and part of the jejunum more than the theory of the anti-diabetic effect of accelerated drive of active undigested food to distally located incretin-triggering receptors α and K \[[@CIT0058], [@CIT0059]\].

This immediate IR improvement seems not to be related to the increased insulin production, which is expected to be the effect of the postprandial incretin reaction, but is associated rather with the correction of fasting hyperinsulinemia \[[@CIT0055], [@CIT0056], [@CIT0060]\]. The increased sensitivity to insulin is considered therefore as an important component of HOMA-IR which is improved rapidly after the operation in the period when patients do not start eating \[[@CIT0027], [@CIT0032]\].

The influence of the length of the excluded part of the digestive tract on the dynamics of glucose metabolism improvement may also be an intriguing issue for reflection.

Some studies \[[@CIT0061], [@CIT0062]\] have demonstrated better T2DM resolution after RYGB where the bilio-pancreatic limb was constructed longer than the traditional 50--100 cm, maintaining the same alimentary limb. Complete diabetes remission without anti-diabetic medications was observed more frequently after RYGB with extended BL postoperatively from 1 to 24 months also in our material \[[@CIT0063]\]. Though the shortened (by elongating the BL) common channel might have a beneficial influence on glycemia control by reducing the food content absorption area in long-term observation, shortly after RYGB when the nourishment volume is extremely restricted anyway, that part of the intestine with extended undiluted bile passage may instead play a role in immediate glucose metabolism improvement \[[@CIT0063]\].

Moreover, the basic aim of BPD/DS was not only to maintain a limited distance for the common bile and food flow but in contrast to long limb Roux en Y gastric bypass to exclude a longer BL than AL \[[@CIT0064]\]. It has been shown that this combination of GI tract modification provides more complete and long-term T2DM remission, with a comparable risk of nutritional deficiency \[[@CIT0034]\].

Finally, the link between the extended space for the separated bile passage and the progressive glycemic control has been exposed also after the recently widely promoted variety of GB -- one-anastomosis gastric bypass. This evolved from the mini gastric bypass, originally described by Rutledge \[[@CIT0038]\], a bariatric operation which although anatomically considered to be only a modification of GB, metabolically imitates a more aggressive form of bariatric surgery -- BPD/DS \[[@CIT0039]\].

The resemblance to RYGB is derived from the scale of the restriction and from the proportionally longer common limb, which result in a lower risk of malnutrition than after BPD/DS. The 2--3 times longer BL created in OAGB is believed to alter more intensively the postoperative metabolic response than after Roux-en-Y type \[[@CIT0039]\].

The propagators of OAGB such as Lee or Garcia-Caballero favor its better anti-diabetic competence over RYGB in mid- and long-term observation \[[@CIT0037], [@CIT0038]\].

Weiner *et al*. appreciated its effectiveness and recommended it beside BPD/DS as the procedure of choice to complete the bariatric management after failed sleeve gastrectomy \[[@CIT0065]\].

The present authors, encouraged by the mid- and long-term benefits of OAGB, included a group of patients operated on by this method in the present study, intending to assess the influence of extended transit of concentrated bile on IR improvement in the ultra-short, short and early postoperative period.

The HOMA-IR change in the period between the day of admission and the 4th day was the most remarkable after OAGB (--Δ63% vs. --Δ56% after RYGB and --Δ41% after SG). Correlating these findings with the long-term results demonstrating the improvement of glucose metabolism may lead to the conclusion that the processes occurring in the excluded duodenum and part of the jejunum may play the crucial role in glucose homeostasis after GB procedures \[[@CIT0066]\].

The mechanism of rapid IR improvement after GB consistent with the "foregut theory" still requires explanation.

Since Troy *et al*. proposed in an animal model \[[@CIT0067]\] the reliable hypothesis of a key role of fasting intestinal gluconeogenesis in an incretin-independent mechanism of increasing the sensitivity to insulin after GB, it has not been supported univocally in human studies \[[@CIT0068]\].

The beneficial metabolic effect after duodeno-jejunal exclusion on glycemic control may be attributed to the substantially high undiluted bile concentration in the intestinal section proximally to the anastomosis where the bile is mixed together with food \[[@CIT0066]\]. The bile ingredients therefore, reabsorbed and transferred via the portal vein system, may carry the intensified signal to change the insulin resistance in the liver and other metabolically active organs or tissues \[[@CIT0069]\]. It has been reported by Le Roux\'s group \[[@CIT0032]\] that reabsorbed primarily bile acids can function as hormones through the farnesoid X receptor or G protein-coupled bile acid receptor 1 and affect the glucose and lipid transformations. Bearing in mind the fact that ca 400--800 ml of bile can be produced and delivered to the alimentary tract daily, contained undiluted in the proximal intestine it may constitute a powerful hormonally active system determining glucose homeostasis \[[@CIT0066], [@CIT0069]\].

Although many surgeons intuitionally tend to prolong the BL in different operative solutions in T2DM patients, the assessment of the correlation between the length of the excluded BL and the strength of the signaling coming from the reabsorbed bile components leading to the IR improvement would facilitate our understanding of the potential role of bile in metabolic regulation.

Conclusions {#S0006}
===========

Among all the factors generated by the bariatric management of obese individuals with glucose intolerance, the type of operation is recognized as the most important in insulin resistance improvement based on HOMA-IR assessment. The most significant change is observed on the 4^th^ day after the surgery and therefore is not dependent on the weight/fat reduction, and the role of the incretin mechanism is questionable because of fasting from caloric food intake. The significant difference in the ultra-fast and early response after restrictive sleeve gastrectomy vs both types of gastric bypass supports the conception of metabolic competence of duodeno-jejunal exclusion.

Altered bile flow after duodeno-jejunal exclusion may be responsible for the enhanced glucose metabolism improvement in postoperatively fasting patients. The reabsorption of the bile ingredients facilitating the rapid metabolic response may be more intensive in a longer biliary limb. Further investigation of the influence of bile activity in the bypassed jejunum on glucose homeostasis is necessary to thoroughly analyze the gastro-intestinal anti-diabetic mechanisms.
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